Glucocorticoid chronotherapy in rheumatoid arthritis

The Lancet

Volumn 371, Issue 9608, 2008, Pages 183-184

  Bijlsma, Johannes WJ ^a   Jacobs, Johannes WG ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; METHOTREXATE; PREDNISONE;

ARTHRALGIA; ARTICLE; CHRONOBIOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MORNING STIFFNESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

EID: 38149052341     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60114-2     Document Type: Note

References (15)

1. Buttgereit F., Doering G., Schaeffler A., et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 371 (2008) 205-214
2. Crofford L., Kalogeras K., Mastorakos G., et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 82 (1997) 1279-1283
3. Straub R., and Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum 56 (2007) 399-408
4. Maini R., Taylor P., Szechinski J., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006) 2817-2829
5. Arvidson N., Gudbjornsson B., Larsson A., and Hallgren R. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis 56 (1997) 27-31
6. Kirwan J., Bijlsma J., Boers M., and Shea B. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 1 (2007) CD006356
7. Van Everdingen A., Jacobs J., Siewertsz Van Reesema D., and Bijlsma J. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136 (2002) 1-12
8. Jacobs J., Van Everdingen A., Verstappen S., and Bijlsma J. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 54 (2006) 1422-1428
9. da Silva J., Jacobs J., Kirwan J., et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 65 (2006) 285-293
10. Hoes J., Jacobs J., Boers M., et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66 (2007) 1560-1567
11. Combe B., Landewe R., Lukas C., et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66 (2007) 34-45
12. Smolen J., Aletaha D., Koeller M., Weisman M., and Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 370 (2007) 1861-1874
13. Verstappen S., Jacobs J., van der Veen M., et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission: computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66 (2007) 1443-1449
14. Bakker M., Jacobs J., Verstappen S., and Bijlsma J. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 66 suppl 3 (2007) iii56-iii60
15. Bijlsma J., and Weinblatt M. Optimal use of methotrexate: the advantages of tight control. Ann Rheum Dis 66 (2007) 1409-1410